Catabasis Pharmaceuticals Inc

Catabasis Pharmaceuticals Inc: Rare disease pipeline; Top-line results expected 2020 from ongoing Ph 3 trial of Edasalonexent in in DMD regardless of mutation type. North Star Ambulatory Assessment as primary endpt based on Ph 2 results and FDA input.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase III
Disease Space
Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Profiles:
Address:
One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, MA 02139
United States

Company Participants at Catabasis Pharmaceuticals Virtual KOL Event - Sep. 11, 2020

  • Jill C Milne, PhD, President/CEO/Co-Founder

Top 10 Holders of Catabasis Pharmaceuticals Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Federated Global Investment Management Corp. 9.17 1,562,500 4.27 Stakes 10/31/20
The Vanguard Group, Inc. 4.83 823,518 2.25 Funds 12/31/20
Vanguard Group, Inc. (Subfiler) 4.57 779,079 2.13 13F 9/30/20
BlackRock Fund Advisors 3.50 596,762 1.63 13F 9/30/20
BlackRock Institutional Trust Co. NA 2.29 389,544 1.06 13F 9/30/20
Fidelity Management & Research Co. LLC 2.17 369,200 1.01 13F 9/30/20
Samsara Biocapital LLC 1.76 300,000 0.82 13F 9/30/20
Northern Trust Corp. 1.72 293,422 0.80 13F 9/30/20
SV Health Investors LLC 1.68 285,765 0.78 13F 9/30/20
Dimensional Fund Advisors LP 1.53 261,221 0.71 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.